- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12. | Goldman Sachs bekräftigt Kaufempfehlung für Rapport Therapeutics nach Studienerfolg bei Epilepsie-Medikament | 5 | Investing.com Deutsch | ||
| 19.12. | Rapport Therapeutics stock holds Buy rating at Goldman Sachs on epilepsy drug efficacy | 1 | Investing.com | ||
| 09.12. | H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data | 1 | Investing.com | ||
| RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.12. | Starke Studiendaten: H.C. Wainwright hebt Kursziel für Rapport Therapeutics auf 40 $ an | 8 | Investing.com Deutsch | ||
| 08.12. | Rapport Therapeutics: Citizens bestätigt "Market Outperform"-Rating nach neuen Studiendaten | 1 | Investing.com Deutsch | ||
| 05.12. | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures | 1 | GlobeNewswire (USA) | ||
| 06.11. | Rapport Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.09. | Truist Securities initiates Rapport Therapeutics stock with Buy rating | 5 | Investing.com | ||
| 11.09. | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | 1 | GlobeNewswire (USA) | ||
| 10.09. | Rapport Therapeutics prices $250M stock at $26 per share | 2 | Seeking Alpha | ||
| 10.09. | Rapport Therapeutics prices $250 million public offering at $26 per share | 2 | Investing.com | ||
| 10.09. | Rapport Therapeutics, Inc.: Rapport Announces Pricing of Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09. | Rapport Therapeutics launches $250 million public stock offering | 15 | Investing.com | ||
| 08.09. | Rapport Therapeutics, Inc.: Rapport Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09. | Rapport Therapeutics: Stifel hebt Kursziel nach Studienerfolg deutlich auf 56 $ an | 2 | Investing.com Deutsch | ||
| 08.09. | Stifel raises Rapport Therapeutics stock price target to $56 on positive trial data | 2 | Investing.com | ||
| 08.09. | Rapport Therapeutics Stock Rises To 117% After Positive Phase 2a Trial Results | 3 | RTTNews | ||
| 08.09. | TD Cowen bestätigt Kaufempfehlung für Rapport Therapeutics nach starken Studiendaten | 3 | Investing.com Deutsch | ||
| 08.09. | Rapport Therapeutics stock rating reiterated as Buy by TD Cowen | 16 | Investing.com |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MICROBOT MEDICAL | 1,849 | +3,47 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,402 | +4,23 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| CAPRICOR | 23,600 | +3,06 % | Capricor +727%: Biotech-Tipp schlägt heftig ein! | Capricor Therapeutics macht heute nicht nur mit positiven Studiennews auf sich aufmerksam: Dank eines gigantischen Multibagger-Kursfeuerwerks sorgt mein Biotech-Tipp aus dem Juli für glückselige Follower.... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,952 | -1,82 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care | Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (=2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,520 | +6,10 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| DBV TECHNOLOGIES | 3,175 | -14,19 % | DBV Technologies S.A.: DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years | Châtillon, France, December 16, 2025
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years
VITESSE... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 103,37 | -2,32 % | Palvella Therapeutics Inc.: Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Angiokeratomas | Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need With Fast Track designation, QTORIN rapamycin for... ► Artikel lesen | |
| ADICET BIO | 0,378 | +1,29 % | Adicet Bio, Inc. Announces Reverse Stock Split | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,435 | +3,24 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 13,200 | +3,12 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Approval of EKTERLY (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY (sebetralstat)... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,400 | -8,47 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen | |
| QUANTUM-SI | 1,230 | -6,11 % | Quantum-Si stock rating reiterated by H.C. Wainwright on Proteus potential | ||
| PROTARA THERAPEUTICS | 4,680 | +5,88 % | Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 5,050 | -0,98 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination | The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combination... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 41,200 | 0,00 % | Crinetics Pharmaceuticals, Inc.: Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) | Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAHSAN DIEGO, Dec. 11, 2025(Nasdaq: CRNX) today announced that... ► Artikel lesen |
Das Unternehmen RAPPORT THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 30,200 Euro und damit -2,36 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.